Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors

SAN FRANCISCO & SHANGHAI–(BUSINESS WIRE)–Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointments of Eric Dobmeier and Joanne Waldstreicher, M.D., to its Board of Directors.

�We welcome both Eric and Joanne, who will be invaluable to us in our company growth and evolution,” said Raymond Stevens, CEO of Structure Therapeutics. “Eric’s significant hands-on business and corporate experience building biotech companies with powerful technology platforms will help us capitalize on our own platform potential. With Joanne’s deep leadership in large chronic disease drug development, her expertise and guidance will be vital for us as we build our GLP-1 franchise and develop our lead GSBR-1290 program further into clinical development.“

Mr. Dobmeier brings over two decades of experience leading biotech companies through key periods of growth. He currently serves as CEO of Chinook Therapeutics, focused on the development of novel therapies for kidney disease, where he led the company’s transition from private to public and raised over $500 million in capital. Prior to this, Mr. Dobmeier held successive leadership positions at Seattle Genetics, including Chief Operating Officer and Chief Business Officer. While at Seattle Genetics, he was directly involved in raising more than $1.2 billion and completed multiple corporate alliances with leading biotechnology and pharmaceutical companies. He currently serves on the board of Atara Therapeutics. Mr. Dobmeier earned his J.D. from the University of California, Berkeley School of Law and A.B. in History from Princeton University.

Dr. Waldstreicher brings over 30 years of experience in various clinical and strategic leadership roles at Johnson & Johnson and Merck & Co. As Chief Medical Officer at Johnson & Johnson, she provides critical leadership in late-stage clinical development in metabolism and cardiovascular disease as well as other therapeutic areas. In addition to her efforts in pipeline development, Dr. Waldstreicher has a successful track record in building global R&D and medical affairs teams. Before Johnson & Johnson, she led endocrinology and metabolism clinical research at Merck Research Laboratories, overseeing development programs in multiple indications, including diabetes, where she was honored with the Key Innovator Award. She has authored over 55 publications, holds numerous patents, and has established herself as a thought leader in bioethics and patient-centered clinical development. Dr. Waldstreicher earned her M.D. from Harvard Medical School and B.A. in Chemistry from Brooklyn College, City University of New York.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. By leveraging its next generation structure-based drug discovery platform, the company has built a pipeline including two clinical-stage small molecule compounds designed to overcome the limitations of biologics and peptide therapies. The company is currently focused on the GPCR family of drug targets. For more information, visit www.structuretx.com and follow the company on Twitter @StructureTx and LinkedIn.

Contacts

Media
Ian Stone

Canale Communications

media@structuretx.com

Other inquiries:
Melita Sun Jung

Chief Business Officer

info@structuretx.com